OM vs. INMD, IRMD, EMBC, TNDM, AXGN, SIBN, BVS, AVNS, ZIMV, and KIDS
Should you be buying Outset Medical stock or one of its competitors? The main competitors of Outset Medical include InMode (INMD), iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), and OrthoPediatrics (KIDS). These companies are all part of the "medical equipment" industry.
Outset Medical vs. Its Competitors
Outset Medical (NASDAQ:OM) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.
In the previous week, InMode had 3 more articles in the media than Outset Medical. MarketBeat recorded 4 mentions for InMode and 1 mentions for Outset Medical. Outset Medical's average media sentiment score of 1.77 beat InMode's score of 0.84 indicating that Outset Medical is being referred to more favorably in the media.
Outset Medical has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500. Comparatively, InMode has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.
68.0% of InMode shares are owned by institutional investors. 2.4% of Outset Medical shares are owned by insiders. Comparatively, 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Outset Medical presently has a consensus target price of $24.67, suggesting a potential upside of 73.95%. InMode has a consensus target price of $18.04, suggesting a potential upside of 22.73%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than InMode.
InMode has higher revenue and earnings than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
InMode has a net margin of 44.50% compared to Outset Medical's net margin of -82.06%. InMode's return on equity of 18.38% beat Outset Medical's return on equity.
Summary
InMode beats Outset Medical on 11 of the 16 factors compared between the two stocks.
Get Outset Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Outset Medical Competitors List
Related Companies and Tools
This page (NASDAQ:OM) was last updated on 9/20/2025 by MarketBeat.com Staff